Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 9/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 3/20 | 0.45 |
| ▸ | CA2 | P00918 | 3/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7100122 | 1.00 | P2RX7 (0.49) | P2RX7LMNACA1CA2CYP2C9 | |
| SCHEMBL7100119 | 1.00 | P2RX7 (0.49) | P2RX7LMNACA1CA2CYP2C9 | |
| SCHEMBL3652010 | 0.86 | P2RX7 (0.51) | P2RX7LMNACA1CA2MAPT | |
| SCHEMBL22552853 | 0.86 | P2RX7 (0.51) | P2RX7LMNACA1CA2MAPT | |
| SCHEMBL3652008 | 0.86 | P2RX7 (0.51) | P2RX7LMNACA1CA2MAPT | |
| SCHEMBL3957822 | 0.85 | P2RX7 (0.54) | P2RX7LMNACTSL | |
| SCHEMBL4972042 | 0.84 | P2RX7 (0.54) | P2RX7LMNAALDH1A1CTSL | |
| SCHEMBL3948746 | 0.84 | P2RX7 (0.54) | P2RX7LMNAALDH1A1CTSL | |
| SCHEMBL9476901 | 0.84 | CTRB1 (0.56) | P2RX7LMNACA1CA2CTSL | |
| SCHEMBL28450226 | 0.84 | P2RX7 (0.50) | P2RX7LMNACA1CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306110-A1 | Alkylnitrile Quinolines as Nk-3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| US-20080306110-A1 | Alkylnitrile Quinolines as Nk-3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| WO-2007035157-A1 | ALKYLNITRILE QUINOLINES, AS NK-3 RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2007-03-29 | — | — | WO | disclosed |
| EP-0811616-B1 | Salts of 3-(2-(4-(4-(Amino-imino-methyl)-phenyl)-4-methyl-2,5-dioxo-imidazolidin-1-yl)-acetylamino)-3-phenyl-propionic acid ethylester | AVENTIS PHARMA GMBH (DE) | 2005-05-04 | — | — | EP | disclosed |
| EP-1183241-B1 | SPIROIMIDAZOLIDINE DERIVATIVES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | AVENTIS PHARMA GMBH (DE) | 2003-09-17 | — | — | EP | disclosed |
| US-6399643-B1 | ANTIINFLAMMATORY AGENTS; ANTIARTHRITIC AGENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-06-04 | — | — | US | disclosed |
| EP-0729460-B1 | SUBSTITUTED 5-RING HETEROCYCLES, THEIR PREPARATION AND THEIR USE | HOECHST AG (DE) | 2002-05-15 | — | — | EP | disclosed |
| EP-1183241-A1 | SPIROIMIDAZOLIDINE DERIVATIVES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | Aventis Pharma Deutschland GmbH (DE) | 2002-03-06 | — | — | EP | disclosed |
| US-6294562-B1 | AMIDINO COMPOUNDS WITH AMIDO ESTERS CARDIOVASCULAR SYSTEM, DISEASES OF THE CORONARY VASCULAR SYSTEM OR THE CEREBROVASCULAR SYSTEM, OR PERIPHERAL ARTERIAL VASCULAR DISEASE | HOECHST AKTIENGESELLSCHAFT (DE) | 2001-09-25 | — | — | US | disclosed |
| US-6191282-B1 | DERIVATIVES OF 5-MEMBERED NITROGEN CONTAINING HETEROCYCLIC RING IS USED AS ANTICARCINOGENIC AGENT AND ANTICOAGULANT | HOECHST MARION ROUSSEL (DE) | 2001-02-20 | — | — | US | disclosed |
| WO-2000069831-A1 | SPIROIMIDAZOLIDINE DERIVATIVES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-11-23 | — | — | WO | disclosed |
| US-5981492-A | ADMINISTERED TO THE PATIENT TO INHIBIT THROMBOCYTE AGGREGATION, THE METASTASIZATION OF CARCINOMA CELLS, THE BINDING OF OSTEOCLASTS TO THE BONE SURFACE, OR FOR THE TREATMENT OF THROMBOSES | HOECHST AKTIENGESELLSCHAFT (DE) | 1999-11-09 | — | — | US | disclosed |
| EP-0811616-A1 | Salts of 3-(2-(4-(4-(Amino-imino-methyl)-phenyl)-4-methyl-2,5-dioxo-imidazolidin-1-yl)-acetylamino)-3-phenyl-propionic acid ethylester | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-12-10 | — | — | EP | disclosed |
| WO-1995014008-A1 | SUBSTITUTED 5-RING HETEROCYCLES, THEIR PREPARATION AND THEIR USE | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306110-A1 | Alkylnitrile Quinolines as Nk-3 Receptor Ligands | KCNQ3, TACR2, TACR3 | P2RX7 192/4885LMNA 1872/4885CA1 3918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.